Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.
| dc.contributor.author | Sezer, Ahmet | |
| dc.date.accessioned | 2022-08-02T12:55:28Z | |
| dc.date.available | 2022-08-02T12:55:28Z | |
| dc.date.issued | 2021 | |
| dc.identifier.endpage | 9078 | en_US |
| dc.identifier.issn | 0732-183X | en_US |
| dc.identifier.issue | 15 | en_US |
| dc.identifier.startpage | 9078 | en_US |
| dc.identifier.uri | http://hdl.handle.net/11727/7204 | |
| dc.identifier.volume | 39 | en_US |
| dc.identifier.wos | 000708120605058 | en_US |
| dc.language.iso | eng | en_US |
| dc.relation.isversionof | 10.1200/JCO.2021.39.15_suppl.9078 | en_US |
| dc.relation.journal | JOURNAL OF CLINICAL ONCOLOGY | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.title | Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study. | en_US |
| dc.type | Conference Object | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: